Homeopathic Regulation Critics Will Swing For Change Against Industry Stalwarts At FDA Hearing
This article was originally published in The Tan Sheet
In addition to marketers and trade groups, Gary Yingling, a former FDA counsel involved in the agency’s decision to omit homeopathics from the OTC drug review, will make a presentation at a public hearing April 20-21. FDA’s current approach as “a rational framework,” CHPA says.
You may also be interested in...
“We ought to deal with this. There are questions on long-term safety and questions on efficacy claims that are just not proven,” says the Maryland Republican. “The biggest threat hanging over, in my mind, the farmers who want to grow hemp, is what if the FDA comes out tomorrow and says, ‘You can't sell any product’? The market collapses,”he said at a CBD policy conference.